The efficacy and safety of Xialiqi capsule in the treatment of type III prostatitis

???????????????????????\?????????

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005243

Enrollment

Unknown

Registered

2021-08-28

Start date

2021-09-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type III prostatitis

Interventions

Experimental group:Xialiqi capsule

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for type III prostatitis. (2) Between 18 and 50 years old.

Exclusion criteria

Exclusion criteria: (1) Patients with acute and chronic bacterial prostatitis and urinary tract infection. (2) Patients with contraindications for drug use (3) Patients who are participating in clinical trials of other drugs; Or participated in a clinical trial of a drug within the last month. (4) Other patients judged by the investigator to be unsuitable to participate in the clinical study.

Design outcomes

Primary

Measure	Time frame
NIH-CPSI;	—

Countries

China

Contacts

Public ContactXinjun Su

512100668@qq.com13697326659

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026